Focus:
Oncology
-
3 June 2020 projects
QINLOCK (ripretinib) for the Treatment of Gastrointestinal Stromal Tumour
QINLOCK™ (ripretinib) is indicated as a fourth-line treatment for advanced gastrointestinal stromal tumour (GIST) in adult patients who have completed previous treatment with three or more kinase inhibitors, including imatinib.
-
21 May 2020 News
Funding secured for UK clinical trial in children with neuroblastoma
A team from the University of Birmingham will organise the UK arm of a critical European clinical trial for children diagnosed with a rare and aggressive childhood cancer called neuroblastoma.
-
19 May 2020 projects
Retevmo (selpercatinib) for the Treatment of RET-Driven Cancers
Retevmo™ (selpercatinib) is the first therapy approved for the treatment of three rearranged during transfection (RET)-driven cancer indications.
-
13 May 2020 News
Sanofi’s Sarclisa meets primary goal in multiple myeloma trial
Sanofi has reported positive data from the Phase III IKEMA clinical trial of Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone to treat patients with relapsed multiple myeloma.
-
11 May 2020 projects
Trodelvy (sacituzumab govitecan) for the Treatment of Advanced Triple-Negative Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is the first and the only approved antibody-drug conjugate for the treatment of advanced triple-negative breast cancer (TNBC) in adult patients.
-
7 May 2020 News
Innovent and Eli Lilly’s trial of TYVYT meets primary endpoint
Innovent Biologics and Eli Lilly and Company have reported positive results from the ORIENT-12 Phase III trial of TYVYT, Gemzar and platinum chemotherapy combination in metastatic squamous non-small cell lung...
-
1 May 2020 projects
Pemazyre™ (pemigatinib) for the Treatment of Cholangiocarcinoma
Pemazyre™ (pemigatinib) is the first and only US Food and Drug Administration (FDA)-approved kinase inhibitor indicated for the treatment of cholangiocarcinoma.
-
24 April 2020 projects
TUKYSA™ (tucatinib) for the treatment of HER2-Positive Breast Cancer
TUKYSA™ (tucatinib) is the first HER-2 tyrosine kinase inhibitor approved in combination with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer.
-
17 April 2020 projects
Koselugo (selumetinib) for the Treatment of Neurofibromatosis Type 1 (NF1)
Koselugo® (selumetinib) is the first FDA-approved drug indicated for the treatment of neurofibromatosis type 1 (NFI), a rare and incurable genetic condition, developed and commercialised globally by AstraZeneca and Merck (MSD)...
-
9 April 2020 projects
Sarclisa (isatuximab-irfc) for the Treatment of Multiple Myeloma
Sarclisa® (isatuximab-irfc) is a monoclonal antibody in combination with pomalidomide and dexamethasone (pom-dex) indicated for the treatment of multiple myeloma.